Expand IMUX Menu
IMUX MENU

IMUX Latest Press Releases

-- June 10, 2026 --

Immunic to Participate in Investor, Industry and Scientific Conferences in June PRNewswire 6:30 AM

-- May 28, 2026 --

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis PRNewswire 6:30 AM

-- May 27, 2026 --

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer PRNewswire 6:30 AM

-- May 19, 2026 --

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors PRNewswire 6:30 AM

-- May 13, 2026 --

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update PRNewswire 6:30 AM

-- April 30, 2026 --

Immunic to Participate in Investor and Medical Conferences in May PRNewswire 6:30 AM

-- April 28, 2026 --

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer PRNewswire 6:30 AM

-- April 23, 2026 --

Immunic, Inc. Announces 1-for-10 Reverse Stock Split PRNewswire 8:02 AM
Immunic, Inc. Announces 1-for-10 Reverse Stock Split PRNewswire 8:01 AM

-- April 9, 2026 --

Immunic to Participate in Scientific and Medical Conferences in April PRNewswire 6:30 AM

-- April 1, 2026 --

Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement PRNewswire 6:30 AM

-- March 31, 2026 --

Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton PRNewswire 6:30 AM

-- March 10, 2026 --

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium PRNewswire 6:30 AM

-- March 3, 2026 --

Immunic to Participate in Investor Conferences in March PRNewswire 6:30 AM

-- February 26, 2026 --

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update PRNewswire 6:30 AM

-- February 17, 2026 --

Immunic Announces Closing of Oversubscribed Private Placement Financing PRNewswire 4:05 PM

-- February 13, 2026 --

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company PRNewswire 6:30 AM

-- February 4, 2026 --

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis PRNewswire 6:30 AM
Market Data Delayed 15 Minutes